Daniela Regazzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3325811/publications.pdf

Version: 2024-02-01

471371 501076 30 851 17 28 citations h-index g-index papers 31 31 31 1304 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype. PLoS Genetics, 2013, 9, e1003350.	1.5	125
2	The (193–209) 17â€residues peptide of bovine βâ€casein is transported through Cacoâ€⊋ monolayer. Molecu Nutrition and Food Research, 2010, 54, 1428-1435.	ılar 1.5	104
3	A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype. Endocrine, 2017, 55, 959-968.	1.1	62
4	The Glucose-Dependent Insulinotropic Polypeptide Receptor is Overexpressed Amongst GNAS1 Mutation-Negative Somatotropinomas and Drives Growth Hormone (GH)-Promoter Activity in GH3 Cells. Journal of Neuroendocrinology, 2011, 23, 641-649.	1.2	39
5	The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gspâ°° somatotropinomas. European Journal of Endocrinology, 2017, 176, 543-553.	1.9	39
6	Large Genomic Rearrangements of Desmosomal Genes in Italian Arrhythmogenic Cardiomyopathy Patients. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	35
7	Acromegaly Is More Severe in Patients With <i>AHR</i> or <i>AIP</i> Gene Variants Living in Highly Polluted Areas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1872-1879.	1.8	34
8	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2021, 9, 813-824.	5.5	34
9	Activation of the Dopamine Receptor Type-2 (DRD2) Promoter by 9-Cis Retinoic Acid in a Cellular Model of Cushing's Disease Mediates the Inhibition of Cell Proliferation and ACTH Secretion Without a Complete Corticotroph-to-Melanotroph Transdifferentiation. Endocrinology, 2014, 155, 3538-3549.	1.4	32
10	Early recognition of aggressive pituitary adenomas: a single-centre experience. Acta Neurochirurgica, 2018, 160, 49-55.	0.9	32
11	Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma. Endocrine, 2018, 59, 510-519.	1.1	32
12	First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS. Journal of Endocrinological Investigation, 2017, 40, 753-760.	1.8	30
13	AHR Over-Expression in Papillary Thyroid Carcinoma: Clinical and Molecular Assessments in a Series of Italian Acromegalic Patients with a Long-Term Follow-Up. PLoS ONE, 2014, 9, e101560.	1.1	27
14	Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. Pituitary, 2020, 23, 359-366.	1.6	25
15	Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 856-862.	1.8	23
16	A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC. Oncotarget, 2015, 6, 32104-32114.	0.8	23
17	Fermented milks fromEnterococcus faecalisTH563 andLactobacillus delbrueckiisubsp.bulgaricusLA2 manifest different degrees of ACE-inhibitory and immunomodulatory activities. Dairy Science and Technology, 2010, 90, 469-476.	2.2	22
18	Diagnostic Accuracy of CT Texture Analysis in Adrenal Masses: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 637.	1.8	22

#	Article	IF	CITATIONS
19	Diagnostic accuracy of increased urinary cortisol/cortisone ratio to differentiate ACTHâ€dependent Cushing's syndrome. Clinical Endocrinology, 2017, 87, 500-507.	1.2	19
20	The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 165-183.	2.6	17
21	Investigation of N-cadherin/β-catenin expression in adrenocortical tumors. Tumor Biology, 2016, 37, 13545-13555.	0.8	14
22	Gonadotropin secreting pituitary adenoma associated with erythrocytosis: case report and literature review. Hormones, 2014, 13, 131-139.	0.9	13
23	Clinical presentation and management of acromegaly in elderly patients. Hormones, 2021, 20, 143-150.	0.9	11
24	The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings. Endocrine-Related Cancer, 2022, 29, 273-284.	1.6	9
25	Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. Pituitary, 2020, 23, 534-542.	1.6	7
26	Allelic Variants of ARMC5 in Patients With Adrenal Incidentalomas and in Patients With Cushing's Syndrome Associated With Bilateral Adrenal Nodules. Frontiers in Endocrinology, 2020, 11, 36.	1.5	7
27	Silent gonadotroph pituitary neuroendocrine tumor in a patient with tuberous sclerosis complex: evaluation of a possible molecular link. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.2	7
28	Different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia. Minerva Endocrinologica, 2019, 44, 205-220.	1.7	4
29	The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas. International Journal of Molecular Sciences, 2022, 23, 6469.	1.8	2
30	Incretin Response to Mixed Meal Challenge in Active Cushing's Disease and after Pasireotide Therapy. International Journal of Molecular Sciences, 2022, 23, 5217.	1.8	1